Eurosets, a company based in Medolla, Italy and a leader in the development, production and commercialization of advanced medical devices, announced that the first patient has been treated with Colibrì, the lightest extracorporeal life support (ECLS) system available in the market.

Colibrì received CE-Mark in October 2022 and complements and expands Eurosets ECLS portfolio with the objective to provide temporary support to patients suffering from ventricular failure, cardiac arrest or respiratory failure in a variety of different applications, including extracorporeal membrane oxygenation (ECMO), extracorporeal cardiopulmonary resuscitation (E-CPR) and mechanical circulatory support (MCS).

The first clinical procedure using Colibrì was performed by a team led by Dr Philippe Gaudard, head of the ICU department at the Arnaud de Villeneuve university Hospital of Montpellier, France. The patient was supported on VA-ECMO and successfully weaned after few days of treatment.

“I truly believe that Colibrì has the potential to become the new standard of care for ECLS,” said Dr Gaudard. “Colibrì, with its lightweight design, ensures that ECLS can be delivered by the specialised mobile ECMO team whenever and wherever is needed and, through its unique features, allows us to initiate ECMO therapy in a safe, easy and reproducible way with advanced monitoring”.

Featuring a fully magnetic-levitating centrifugal pump that covers adult, paediatric and new-born patients, a series of advanced monitoring capabilities and a complete integration with ECMOLife, Colibrì is the lightest device available in the market. The breakthrough device developed by Eurosets is also equipped with a wi-fi connection that allows innovative remote monitoring, thereby ensuring greater patient safety and easier management for healthcare professionals. The device has a set of unique transport accessories designed to perform ECLS even in the most difficult scenarios.

Colibrì is currently being introduced in selected European centres as part of a controlled launch, after which a full international commercial release will follow upon achievement of local approvals.